



Jesse Stoakes Research Award

2008 Stoakes Student Research

Midwest Cardiovascular Research Foundation, Davenport, announced the 2008 recipients of the Jesse Stoakes Student Research Awards for its 8-week summer session.

Anita Ahuja has completed her freshman year at Knox College, Galesburg, Ill. and plans to become a pediatrician. Anita worked this past summer on stenting of unprotected left main using drug eluting stents.

Linsey Ross has completed her freshman year at the University of Iowa, Iowa City and plans to pursue a career in cardiology. Linsey worked this past summer on the predictors of restenosis in the superficial artery.

Cara Voelliger has completed her freshman year at Drake University, Des Moines and plans to pursue a medical career. Cara worked this past summer on

stenting of unprotected left main using drug eluting stents.

Anup Parikh was our volunteer students in 2008. Anup worked this past summer with Dr. Nicolas W. Shammam on trifurcating coronary artery disease using drug eluting stents.

The Stoakes Student Research Award was established in 2006 in memory of Jesses Stoakes, son of Penny and David Stoakes of Bettendorf, who had an avid interest in cardiovascular medicine. He died at age 16 of injuries suffered in an automobile accident.

Midwest Cardiovascular Research Foundation was established in 2002 by Nicolas W. Shammam, MD, MS, as a 501(c)(3) non-profit, tax-exempt scientific and educational foundation dedicated to heart health, education and awareness through quality research and professional and community education programs and projects.



In This Issue...

- Jesse Stoakes Research 2008 Award..... 1**
- Clinical Trials2, 3**
- CIPG 2008 Conference.....4**
- Welcoming Dr. Eric Dippel.....5**
- MCRF Publications6 & 7**
- MCRF Board of Directors8**
- MCRF Donation Form9**


Clinical Trials

Over 24 clinical trials are currently conducted at MCRF. These include peripheral vascular disease, carotid disease, coronary artery disease, congestive heart failure, hypertension, anticoagulants, NSAIDs and others. The following clinical trails are on-going at MCRF:


- ♥ **ABRAXIS:** A Phase II Trial of ABI-007 (Paclitaxel Albumin-bound Particles) for the Prevention of Restenosis following Revascularization of the Superficial Femoral Artery (SFA)Principal Investigator: Eric Dippel, MD, Clinical Coordinator: Penny Stoakes, RN, Contact Phone Number: 563-324-4384, Sponsor: Spectranetics
- ♥ **CG104 (COGENTUS):** A randomized, double-dummy, parallel group, phase 3 efficacy and safety study of CGT-2168 compared with clopidogrel to reduce upper gastrointestinal events including bleeding and systematic ulcer disease....Principal Investigator: Nicolas W. Shammass, MD, Clinical Coordinator: Lori Christensen, RN, Contact Phone Number: 563-324-4384, Sponsor: Parexel
- ♥ **COSTAR:** (CLOSED) Currently in follow-up stage. Cobalt chromium STent with Antiproliferative for Restenosis II Trial....CLOSED, Direct Stenting will start in February 2007. Principal Investigator: Nicolas W. Shammass, MD, Clinical Coordinator: Denise Coiner, MS, RTR, Contact Phone Number: 563-324-4384, Sponsor: Conor Medsystems
- ♥ **CRESCENDO:** Comprehensive Rimonabant Evaluation Study of Cardiovascular ENDpoints and Outcomes (CRESCENDO).... Principal Investigator: Eric Dippel, MD, Clinical Coordinator: Penny Stoakes, RN, Contact Phone Number: 563-324-4384, Sponsor: Sanofi-Aventis
- ♥ **CHOICE:** Carotid Stenting For High Surgical Risk Patients; Evaluating Outcomes Through The CollectIon of Clinical Evidence ("CHOICE")....Principal Investigator: Eric Dippel, MD, Clinical Coordinator: Penny Stoakes RN, Contact Phone Number: 563-324-4384, Sponsor: Abbott Vascular
- ♥ **CHRONICLE HF:** Implantable Cardioverter Defibrillator....Principal Investigator: Rafat Padaria, MD, Clinical Coordinator: Lisa Decker, RN, BSN, Contact Phone Number: 563-324-4384, Sponsor: Medtronic
- ♥ **CLEARWAY:** Dethrombosis of Lower Extremity Thrombus by Local Delivery of Thrombolysis Using ClearWay Transcatheter Balloon Irrigation: a feasibility and dose finding study....Principal Investigator: Nicolas W. Shammass, MD, Clinical Coordinator: Denise Coiner, MS, RTR, Contact Phone Number: 563-324-4384, Sponsor: Atrium Medical Corporation
- ♥ **CYPHER ELITE:** A Prospective, Single-Blind, Randomized, Multi-Center Study Comparing the CYPHER@ELITE™ to the CY{HER@BxVELOCITY@ Sirolimus-Eluting Stent Systems....Principal Investigator: Eric Dippel, MD, Clinical Coordinator: Desyree Weakley, RN, Contact Phone Number: 563-324-4384, Sponsor: Johnson & Johnson
- ♥ **DEEP EMBOLI:** (CLOSED) This study is currently in follow-up phase. Distal Embolic Event Protection Using Excimer Laser Ablation in Peripheral Vascular Interventions, a pilot registry....Principal Investigator: Nicolas W. Shammass, MD, Clinical Coordinator: Denise Coiner, MS, RTR, Contact Phone Number: 563-324-4384, Sponsor: Spectranetics
- ♥ **PTA vs. ATHRECTOMY:** (Closed to enrollment. Currently in follow-up phase.) A Randomized Trial of Percutaneous Transluminal Angioplasty versus Atherectomy Using the Silverhawk FOXhollow Catheter....Principal Investigator: Nicolas W. Shammass, MD, Clinical Coordinator: Denise Coiner, MS, RTR, Contact Phone Number: 563-324-4384, Sponsor: Midwest Cardiovascular Research Foundation
- ♥ **PRECISION:** A Randomized, Double Blind, Parallel-Group Study of Cardiovascular Safety In Osteoarthritis or Rheumatoid Arthritis Patients With or at High Risk for Cardiovascular Disease Comparing Celecoxib With Naproxen and Ibuprofen **THIS IS AN ARTHRITIS STUDY**....Principal Investigator: Nicolas W. Shammass, MD, Clinical Coordinator: Lori Christensen, RN, Contact Phone Number: 563-324-4384, Sponsor: Pfizer
- ♥ **PERSEUS:** A Prospective Evaluation in a Randomized Trial of the Safety and Efficacy of the Use of the TAXUS@ Element™ Paclitaxel-Eluting Coronary Stent System for the Treatment of De Novo Coronary Artery Lesions...Principal Investigator: Eric Dippel, MD, Clinical Coordinator: Desyree Weakley, RN, Contact Phone Number: 563-324-4384, Sponsor: Boston Scientific Corporation
- ♥ **POLAR CATHETER:** Reduced Stent Utilization with Cryoplasty Using the Pp;ar Catheter versus Plain Old Balloon Angioplasty: A Randomized Trial....Principal Investigator: Nicolas W. Shammass, MD, Clinical Coordinator: Denise Coiner, MS, RTR, Contact Phone Number: 563-324-4384, Sponsor: Boston Scientific, Inc.

Clinical Trials - Continued

- ♥ **ROCHE:** A phase III, double-blind, randomized placebo-controlled study, to evaluate the effects of RO4607381 on cardiovascular risk in the stable CHD patients, with a documented recent Acute Coronary Syndrome.....Principal Investigator: Nicolas W. Shammass, MD, Clinical Coordinator: Lori Christensen, RN, Contact Phone Number: 563-324-4384, Sponsor: Hoffmann-La Roche LTD
- ♥ **SAPPHIRE:** SAPPHIRE WW Stenting And Angioplasty With Protection in Patients at High-Risk For Endarterectomy....Principal Investigator: Eric Dippel, MD, Clinical Coordinator: Penny Stoakes, RN, Contact Phone Number: 563-324-4384, Sponsor: Cordis
- ♥ **ST DETECT:** ST Segment Detection Study....Principal Investigator: Blair Foreman, MD, Clinical Coordinator: Lisa Decker, RN, BSN, Contact Phone Number: 563-324-4384, Sponsor: Medtronic
- ♥ **SATURN:** Study of Coronary Atheroma by InTravascular Ultra-sound: Effecto of Rosuvastatin Versus AtrovastaiN.....Principal Investigator: Eric Dippel, MD, Clinical Coordinator: Desyree Weakley, RN, Contact Phone Number: 563-324-4384, Sponsor: AstraZeneca
- ♥ **STROLL:** Cordis STROLL Study.....Principal Investigator: Eric Dippel, MD, Clinical Coordinator: Penny Stoakes, RN, Contact Phone Number: 563-324-4384, Sponsor: The Medicine Company
- ♥ **TRILOGY:** The TRILOGY ACS Study....Principal Investigator: Nicolas W. Shammass, MD, Clinical Coordinator: Lori Christensen, RN, Contact Phone Number: 563-324-4384, Sponsor: Eli Lilly and Company
- ♥ **VIVA II SALVAGE:** (Closed to enrollment.) A ProSepctive, Multi-center TriAL to Evaluate the Safety and Performance of Spectranetics Laser with Adjunct PTA and GORE VIABAHN® Endoprosthesis for the Treatment of SFA Instent Restenosis....Principal Investigator: Eric Dippel, MD, Clinical Coordinator: Penny Stoakes, RN, Contact Phone Number: 563-324-4384, Sponsor: VPI VIVA Physicians Inc.
- ♥ **VIVA I XCELL:** VIVA I: XCELL Trial XPERT™ NITINOL STENTING FOR CRITICALLY ISCHEMIC LOWER LIMBS....Principal Investigator: Eric Dippel, MD, Clinical Coordinator: Penny Stoakes, RN, Contact Phone Number: 563-324-4384, Sponsor: VIVA Physicians, Inc.
- ♥ **ZoMAXX:** (Closed-Currently in follow-up phase.) A Randomized, Controlled Trial to Evaluate the Safety and Efficacy of the ZoMaxx™ Drug Eluting Coronary Stent System as Compared to TAXUS™ Express²™ Paclitaxel-Eluting Stent in *de novo* Coronary Artery Lesions....Principal Investigator: Nicolas W. Shammass, MD, Clinical Coordinator: Denise Coiner, MS, RTR, Contact Phone Number: 563-324-4384, Sponsor: Abbott Vascular Devices
- ♥ **BIVALIRUDIN in PPI:** In hospital outcomes of patients receiving PPI with Bivalirudin: Experience from 2 Medical Centers.....Principal Investigator: Nicolas W. Shammass, MD, Clinical Coordinator: Gail Shammass, RN, Contact Phone Number: 563-324-4384, Sponsor: The Medicine Company



Pictured Below: Eric J. Dippel, MD
President and Associate Research Director
Midwest Cardiovascular Research Foundation




Pictured Above: Nicolas W. Shammass, MD
Founder and Research Director
Midwest Cardiovascular Research Foundation



Cardiovascular Interventions and Practice Guidelines 2008

Cardiovascular Interventions and Practice Guidelines (CIPG) 2008 is the annual conference of MCRF. This year it was held at the Adler Health Education Center, Genesis Heart Institute, Davenport, Iowa, October 10-11, 2008. Over 160 healthcare professionals benefited from 16 presentations from experts in cardiovascular diseases that included the following 10 speakers:

- ♥ Nicolas W. Shammass, MD, MS (Conference Director)
- ♥ Eric J. Dippel, MD (Conference Director)
- ♥ Blair Foreman, MD (Conference Co-Director)
- ♥ Nick Augelli, MD
- ♥ Danita Harrison, ARNP
- ♥ Mark Kovach, MD
- ♥ Rameshkumar Raman, MD
- ♥ Richard Sadler, MD
- ♥ Peter Sharis, MD
- ♥ Matthew Wilber, DPM
- ♥



The CIPG 2008 learning opportunities covered a wide variety of cardiovascular diseases. The Friday session focused on peripheral vascular diseases, wound management and featured one taped case presented by Eric Dippel, MD on carotid angioplasty and stenting.

The Saturday session, which focused on cardiology, other topics addressed during the conference were lectures on acute coronary syndromes, drug eluting stents, electrophysiology lectures, vulnerable plaques, and management of hypertension, diabetes and lipids. Conference attendees gave the conference rave reviews.

This conference was made possible through the generous contribution of the following:

AGA Medical Corporation, AstraZeneca Pharmaceuticals, Astella Pharmaceuticals, Bard Peripheral Vascular, Inc., Boston Scientific, Cordis Corporation, Ev3, Inc., KCI, Eli Lilly, Medtronic, Novo Nordisk, Sanofi-Aventis, Schering-Plough Corporation, Spectranetics, St. Jude's Medical, Takeda Pharmaceuticals Inc., and The Medicine Company.



Welcoming Dr. Eric Dippel, MD as President of MCRF

On October 1, 2008, Dr. Dippel became the second president of the Midwest Cardiovascular Research Foundation. Dr. Shammass, Founder and first president (2002-2008) noted that “Dr. Dippel brings with him a wealth of experience in research and education. He had tremendous contribution to the Foundation over the past several years and has been part of its growth since its development. Bringing new leadership into the Foundation is of critical importance to keep its long term viability and inject the foundation with new and exciting ideas”. Dr. Shammass will remain the Research Director and Chief Executive Officer of the Foundation overseeing many of its day-to-day operation and overall research operation. The Foundation has grown from one part time employee to now 8 employees. The Foundation has published 3 books, participated in the writing of several book chapters, published over 60 manuscripts and abstracts and its research has been presented nationally and internationally. In addition, numerous educational programs have been developed including the student research program and the chronic limb ischemia council.



Midwest Cardiovascular Research Foundation was established in 2002 by Nicolas W. Shammass, MD, MS, as a 501(c)(3) non-profit, tax-exempt scientific and educational foundation dedicated to heart health, education and awareness through quality research and professional and community education programs and projects.

Welcoming New Additions to the MCRF Family



Pictured above from left to right: Lori Christensen (MCRF Coordinator) and her baby girl. Lisa Decker’s (MCRF Coordinator) husband and her baby girl.

Welcoming Dr. Blair Foreman, MD Investigator-Coordinator Unit to MCRF



Pictured above from left to right: Wendy Excontrias, RN, Lisa Decker, RN, and Dr. Blair Foreman, MD

Recent Publications Carrying MCRF Name

MCRF investigators presented in 2008 a total of 15 abstracts in 2008 at major meetings in the United States including ACC/SCAi2, CRT, NCVH and TCT. "It is a reflection of the active research program that we have at the Foundation. Several investigator-initiated protocols have been developed, launched and conducted by the Foundation's investigators. These studies are of immediate clinical importance to the practicing cardiovascular specialist", Dr Shammass said. The abstracts presented are as follows:

Shammass NW, Dippel EJ, Shammass GA, Jerin M, Bryan D, Rauba J. Does High Sensitivity C-Reactive Protein Predict Target Lesion Revascularization in Patients Undergoing Lower Extremity Percutaneous Interventions? Transcatheter Cardiovascular Therapeutics 2008, Washington DC, October 12-17. American Journal of Cardiology , 102 (8): 227i, TCT-603

Shammass NW, Shammass GA, Dippel EJ, Jerin M, Hahn A, Winter M .In-Hospital Complications and Long Term Safety of The Paclitaxel Drug Eluting Stent in Acute ST Elevation Myocardial Infarction: A Real World Experience From a High-Volume Medical Center. Presented at New Cardiovascular Horizons 2008, September 10-13, New Orleans, Louisiana

Shammass NW, Shammass GA, Dippel EJ, Jerin M. In hospital Outcomes of Patients Undergoing Peripheral Percutaneous Interventions with Subsequent Distal Lower Extremity Atheroembolization. New Cardiovascular Horizons 2008, September 10-13, New Orleans, Louisiana

Shammass NW, Dippel EJ, Shammass GA, Jerin M, Bryan D, Rauba J. Does High Sensitivity C-Reactive Protein Predict Target Lesion Revascularization in Patients Undergoing Lower Extremity Percutaneous Interventions? New Cardiovascular Horizons 2008, September 10-13, New Orleans, Louisiana

Sharis PJ, Voelliger CM; Ahuja A; Vigliotti D, Jerin M, Robken J, Shammass NW. Large Single Center Experience with Unprotected Left Main Coronary Artery Drug-Eluting Stenting in 289 Patients. New Cardiovascular Horizons 2008, September 10-13, New Orleans, Louisiana

Shammass NW, Shammass GA, Jerin M, Parikh A, Coin K, Dippel EJ, Robken J. Treatment of Left Main Trifurcation Coronary Artery Disease with the Paclitaxel-Eluting Stent: Long term Outcome from a Tertiary Medical Center. New Cardiovascular Horizons 2008, September 10-13, New Orleans, Louisiana

Shammass NW, Coiner D, Shammass GA, Dippel EJ, Christensen L. Distal Embolic Event Protection Using Excimer Laser Ablation in Peripheral Vascular Interventions: Preliminary Results of the DEEP EMBOLI Registry. New Cardiovascular Horizons 2008, September 10-13, New Orleans, Louisiana

Shammass NW, Dippel EJ, coiner D , Gayton L, Shammass GA. Preventing Lower Extremity Distal Embolization Using Embolic Filter Protection: Results of the Pilot PROTECT Registry. Presented at ACC/SCAI i2, E. Poster, Chicago, IL, 2008. JACC, 51 (10), Supplement B, B76 (abstract # 2900-234)

Shammass NW, Dippel EJ, Gayton L, Coiner D, Shammass GA, Byrd J, Stoakes P. Prevalence of Thrombus in Patients with a Recent History of Claudication or Rest Limb Pain: An Intravascular Ultrasound Assessment. Presented at CRT 2008, February, Washington DC., CRT 2008, 9:page 116.

Shammass NW, Dippel EJ, coiner D, Stoakes P, Gayton L, Shammass GA. Preventing Lower Extremity Distal Embolization Using Embolic Filter Protection: Results of the Pilot PROTECT Registry. Presented at CRT 2008, February, Washington DC. CRT 2008, 9:page 115.

Shammass NW, Dippel EJ, Coiner D, Gayton D, Shammass GA, Byrd J, Stoakes P. Safety and Effectiveness of the Power-Pulse Spray in Treating Patients with Recent Onset of Claudication and Limb Ischemia. Presented at CRT 2008, February, Washington DC. CRT 2008, 9:page 116.

Shammass NW, Dippel E, Shammass GA, Kumar A, Jerin M, Kennedy L. Utilization of GpIIb/IIIa inhibitors in Peripheral Percutaneous Interventions: Current Applications and in-Hospital Outcomes in a Tertiary Referral Center. Presented at CRT 2008, February, Washington DC.

Shammass NW, Dippel EJ, Sharis P, Robken J, Farland L, Brosius S, Jerin M, Avila A, Gehbauer L, Winter M, Shammass GA, Stoakes P, Byrd J, Kennedy L, Millette LA. Main Branch and Side Branch Stenting versus Provisional One Branch Stenting for Bifurcating Coronary Lesions using the Paclitaxel Drug-Eluting Stent: a single Center Experience with Intermediate term follow-up. Presented at CRT 2008, February, Washington DC. CRT 2008, 9:page 116.

Recent Publications Carrying MCRF Name - Continued

Shammas NW, Coiner , Shammas GA, Dippel EJ. Reduced Stent Utilization with Silverhawk Atherectomy versus Balloon Angioplasty in Patients Undergoing Peripheral Vascular Interventions: a Randomized Trial. Presented at CRT 2008, February, Washington DC. CRT 2008, 9:page 115.

Shammas NW, Dippel EJ, Sharis P, Robken J, Farland L, Brosius S, Jerin M, Avila A, Gehbauer L, Winter M, Shammas GA, Stoakes P, Byrd J, Kennedy L, Millette LA. Long Term Outcomes with Bifurcating Coronary Lesions Stenting using the Paclitaxel Drug-Eluting Stent: a Single Center Experience. Presented at CRT 2008, February, Washington DC. CRT 2008, 9:page 115.

In addition to the abstracts accepted for presentation, 10 manuscripts with MCRF participating have been accepted in peer-reviewed journals including American Journal of Cardiovascular Drugs, JIC, JEVT, Preventive Cardiology, Circulation, Vascular Disease Management, JAMA, and the International Journal of Angiology. These include the following:

Shammas NW, Sica DA, Toth PP. A Guide to the Management of Blood Pressure in the Diabetic Hypertensive Patient. American Journal of Cardiovascular Drugs, (In print 2008)

Shammas NW. Embolization in lower extremity percutaneous interventions: recommendations and strategies for embolic filter protection use. Vascular Disease Management, January/February, 2008;5:22-26

Shammas NW. Peripheral Arterial Disease: book review. Vascular Disease Management, January/February, 2008;5:35-36

Shammas NW, Dippel EJ, Shammas GA, Farland L, Brosius S, Jerin M, Avila A, Gehbauer L, Winter M, Stoakes P, Byrd J, Sharis P, Robken J. Long Term Outcomes with Bifurcating Coronary Lesions Stenting using the Paclitaxel Drug-Eluting Stent: a Single Center Experience. International Journal of Angiology (In print, 2008)

Shammas NW, Dippel EJ, Coiner D, Gayton D, Shammas GA, Byrd J, Stoakes P. Safety and Effectiveness of the Power-Pulse Spray in Treating Patients with Recent Onset of Claudication and Limb Ischemia. J Endovas Ther, 2008;15(5):570-579

MEND-CABG II Investigators, Alexander JH, Emery RW Jr, Carrier M, Ellis SJ, Mehta RN, Hasselblad V, Menasche P, Khalil A, Cote R, Bennett-Guerrero E, mack MJ, Schuler G, Harrington RA, Tardif JC. Efficacy and safety of pyridoxal 5'-phosphate (MC-1) in high-risk patients undergoing coronary artery bypass graft surgery: the MEND-CABG II randomized clinical trial. JAMA. 2008 Apr 16;299(15):1777-87. Epub 2008 Apr 1. (Dr Shammas is listed as one of the principal investigator)

Shammas NW, Dippel EJ, Coiner D, Shammas GA, Jerin M, Kumar A. PReventing LOwer ExTremity Distal Embolization Using EmboliC FilTer Protection: Results of the PROTECT Registry. J Endovas Ther, 2008; 15:270-276

Shammas NW, Dippel EJ, Shammas GA, Kumar A, Jerin M, Kennedy L. Utilization of GpIIb/IIIa inhibitors in Peripheral Percutaneous Interventions: Current Applications and in-Hospital Outcomes in a Tertiary Referral Center. J Invasive Cardiology, 2008; 20:266-269

Shammas NW, Dippel EJ, Jerin M, Toth PP, Kapalis M, Reddy M, Harb H. Elevated Levels of Homocysteine Predict Cardiovascular Death, Non Fatal Myocardial Infarction and Symptomatic Bypass Graft Disease at 2-Year Follow-Up Following Coronary Artery Bypass Surgery. Preventive Cardiology, 2008; 11: 95-99

Cooper CJ, Haller ST, Colver W, Steffes M, Burket MW, Thomas WJ, Safian R, Reedy B, Brewster P, Ankendrandt MA, Vinnani R, Dippel E, Rocha-Singh K, Murphy TP, Kennedy DF, Shapiro JI, D'Agostino RD, Pencina MJ, Khuder S. Embolic protection and platelet inhibition during renal artery stenting. Circulation. 2008 May 27;117(21):2752-60. Epub 2008 May 19.

MCRF Board of Directors

Founder and Research Director Nicolas W. Shammass, MD, MS, is an interventional cardiologist with Cardiovascular Medicine, P.C., Davenport, IA, and a Clinical Assistant Professor at the University of Iowa in Iowa City. He founded MCRF in 2002 to facilitate cardiovascular clinical research and education. He has been active as principal or co-investigator in over 100 research trials, has been a participating author in over 130 publications, and is a popular presenter at international professional meetings.

President and Associate Research Director Eric J. Dippel, MD, is an interventional cardiologist with Cardiovascular Medicine, P.C., Davenport, IA. As principal or co-investigator, he is active in peripheral and endovascular research. Dr. Dippel presents his findings through speeches at professional meetings both nationally and internationally, and as an author in industry publications.

Director Clark Arons, CLU, FIC, Bettendorf, IA, is a Senior Financial Consultant with Thrivent Financial for Lutherans, specializing in money management, estate planning and charitable giving. He is active in the community, serves on many boards and is a motivational speaker for young people.

Director John DeDoncker, Bettendorf, IA, is the President of THE National Bank, Bettendorf, IA. As an attorney and banking executive, he shares his expertise on many community organization boards.

Director Blair Foreman, MD, is a cardiologist and electrophysiologist with Cardiovascular Medicine, P.C., Davenport, IA. He actively participates in cardiovascular research projects focusing on electrophysiology.

Director James Kapalis, Bettendorf, IA, is a retired executive of Deere & Company, Moline, IL, and is currently President of Global Supply Chain Solutions, Inc., Bettendorf, IA. He serves as a member of the American Red Cross Disaster Team, and is an active member on many community organization boards.

Director Peter P. Toth, MD, PhD, is the Director of Preventive Cardiology at the Sterling Rock Falls Clinic, in Sterling, IL and editor-in-chief of the *Journal of Applied Research in Clinical and Experimental Therapeutics*. He is active in research and a frequent speaker at national and international professional meetings.

TO CONTACT MCRF.....

Feel free to contact us regarding submitting manuscripts or articles, obtaining publications, booking a speaker, contributing funds or other matters.

To submit manuscripts, discuss research possibilities, etc., contact:

Dr. Nicolas W. Shammass, MD
Founder & Research Director
Editor-in-Chief, Editorial Board
shammass@mchsi.com

For other assistance or information, contact:

Maureen Koepke
Office Manager
563.324.2828
koepkem@mcrfmd.com



We're On The Web!
www.mcrfmd.com

Midwest Cardiovascular Research Foundation

1622 E. Lombard Street
Davenport, IA 52803

Phone: 563.324.2828
Fax: 563.324.2835

MCRF Donation Form

YES, I want to help support Midwest Cardiovascular Research Foundation research projects and education to promote heart health in this community.

First Name

Last Name

Home Phone

E-mail Address

Home Address

City State Zip

- Senior - \$15
- Family - \$25
- Patron - \$100
- Founder - \$500
- Student - \$15
- Sustainer - \$50
- Benefactor - \$250
- Visionary - \$501+
- Individual - \$20
- My employer will match my gift. I enclose the form for the matching gift.

Checks should be payable to Midwest Cardiovascular Research Foundation

GIFTS are a meaningful way to remember someone special. Your gift will be acknowledged by Midwest Cardiovascular Research Foundation to the person/family remembered.

In honor of _____

In memory of _____

Amount enclosed \$ _____

Please send acknowledgement to:

Name

Address

City, State, ZIP



**Midwest Cardiovascular
Research Foundation**

All gifts to MCRF are fully tax deductible under the U.S. Internal Revenue Code.

100% of all gifts are applied to research and education for heart health in this community.

For more information about MCRF
visit www.mcrfmd.com or phone 563.324.2828